Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues

被引：10
|
作者：
Kamal, Ali D. [1 ]
Bain, Stephen C. [1 ]
机构：
[1] Birmingham Heartlands Hosp NHS Fdn, Birmingham B9 5SS, W Midlands, England
来源：
EXPERT OPINION ON DRUG SAFETY | 2007年 / 6卷 / 01期
关键词：
analogue insulin; hypoglycaemia; insulin glulisine;
D O I：
10.1517/14740338.6.1.5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Glulisine insulin is the latest addition to the class of rapid-acting insulin analogues. It is important that it is comparable in safety not only to human regular insulin, but also to the well established analogue insulins, aspart and lispro. In this summary the evidence comparing the safety and efficacy of glulisine with its counterpart insulins in various groups of diabetic patients is discussed.
引用
收藏
页码：5 / 7
页数：3
相关论文
共 50 条
  • [21] Insulin aspart: A new rapid-acting insulin analog
    Setter, SM
    Corbett, CF
    Campbell, RK
    White, JR
    [J]. ANNALS OF PHARMACOTHERAPY, 2000, 34 (12) : 1423 - 1431
  • [22] Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
    Jochen Seufert
    Martin Pfohl
    Anja Borck
    Peter Bramlage
    Thorsten Siegmund
    [J]. Diabetes Therapy, 2021, 12 : 749 - 764
  • [23] CONCENTRATED RAPID-ACTING INSULIN PREPARATIONS
    Handeslman, Yehuda
    [J]. ENDOCRINE PRACTICE, 2017, 23 : 18 - 23
  • [24] Rapid-acting insulin analogues in type 1 diabetics: What guidelines recommend
    Hummel, M.
    Schnell, O.
    [J]. DIABETES STOFFWECHSEL UND HERZ, 2008, 17 (03): : 191 - +
  • [25] Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects
    Becker, RHA
    Frick, AD
    Burger, F
    Potgieter, JH
    Scholtz, H
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (08) : 435 - 443
  • [26] Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: Comparisons with insulin and insulin-like growth factor I
    Ciaraldi, TP
    Phillips, SA
    Carter, L
    Aroda, V
    Mudaliar, S
    Henry, RR
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10): : 5551 - 5558
  • [27] Usefulness of rapid-acting insulin lispro in CSII
    Yanagisawa, K
    Tuchida, KI
    Endo, M
    Masuda, H
    Makita, Z
    Koike, T
    [J]. DIABETES, 2001, 50 : A446 - A446
  • [28] Rapid-acting insulin secretagogues: a clinical need?
    Home, PD
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 : S115 - S119
  • [29] Precision Dosing of Rapid-Acting Insulin Matters
    Aanstoot, Henk-Jan
    Rodriguez, Henry
    Weinzimer, Stuart
    Vint, Nan
    Koeneman, Lisette
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (05) : 346 - 351
  • [30] Use of insulin immunoassays in clinical studies involving rapid-acting insulin analogues: Bi-insulin IRMA preliminary assessment
    Agin, Arnaud
    Jeandidier, Nathalie
    Gasser, Francoise
    Grucker, Daniel
    Sapin, Remy
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2006, 44 (11) : 1379 - 1382
12345